Orexo appoints Nomination Committee and publishes financial calendar 2012/2013
Prior to the Annual General Meeting 2013, Orexo appoints a Nomination Committee which represents approximately 49 percent of the number of shares and votes in the company based on the last known shareholder information.
The Nomination Committee, whose tasks include providing proposals to the General Meeting regarding Chairman of the Meeting, Board members, Chairman of the Board, fees for the board members, any remuneration for committee work, proposal for and fees to the company’s auditor as well as principles for composition of the Nomination Committee, comprises:
- Ulrik Spork, Novo A/S, also Chairman of the Nomination Committee
- Björn Odlander, HealthCap
- Claus Berner Møller, Arbejdsmarkedets Tillaegspension (ATP)
- Martin Nicklasson, Chairman of the Board of Orexo
The Nomination Committee’s proposals will be presented in the Notice to the Annual General Meeting 2013 and on Orexo’s web site, http://www.orexo.com.
Shareholders who want to submit proposals to the Nomination Committee, can do this by sending an e-mail to beata.augenblick@orexo.com (subject “Nomination Committee”) or by letter posted to “Orexo’s Nomination Committee,” Orexo AB, Box 303, SE-751 05 Uppsala, Sweden, by February 15, 2013 at the latest.
The Annual General Meeting 2013 in Orexo will be held on Thursday, April 11, 2013 at 5:00pm CET in Uppsala. Shareholders who want to have a matter addressed at the Annual General Meeting 2013 must submit such a proposal to the same address as above (subject “Annual General Meeting 2013” for the e-mail and the letter, respectively) in sufficient time prior to the notice convening the Annual General Meeting, which is expected to occur at the beginning of March 2013.
Future information reporting dates from Orexo:
| Interim Report January – September 2012 | October 25, 2012 |
| Year-End Report 2012 | January 31, 2013 |
| Annual General Meeting 2013 | April 11, 2013, at 5:00pm CET |
| Interim Report January – March, 2013 | April 26, 2013 |
| Interim Report January – June, 2013 | July 12, 2013 |
| Interim Report January – September, 2013 | October 23, 2013 |
For more information, please contact:
Carl-Johan Blomberg, SVP och CFO
Tel: +46 (0)706-33 67 11
E-mail: carl-johan.blomberg@orexo.com
Beata Augenblick, Investor Relations
Tel: +46 (0)706-22 59 93
E-mail: beata.augenblick@orexo.com
About Orexo
Orexo AB is an emerging specialty pharmaceutical company developing improved treatments using proprietary drug delivery technology. Orexo’s expertise is within the area of reformulation technologies and especially sublingual formulations. The company has a portfolio of revenue-generating EU and US approved products currently marketed under licence and a pipeline of several reformulations of approved compounds for areas of unmet medical need. Orexo also has collaboration projects with several international pharma companies. Orexo AB, with its headquarters in Sweden, is listed on NASDAQ-OMX. The largest shareholders are Novo A/S and HealthCap. More information can be found at www.orexo.com.
Note
Orexo AB (publ) discloses the information provided in this press release pursuant to the Securities Markets Act. The information was provided for public release on October 11, 2012 at 09.00a.m. CET. This press release has been prepared in both Swedish and English. In the event of any discrepancy in the content of the two versions, the Swedish version shall take precedence.
Tags: